-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ipsen (ipsen) recently signed a license agreement with IRLAB to obtain the exclusive global development and commercialization rights for a new dopamine D3 receptor antagonist mesdopetam (IRL790)
Original source: Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson's disease
Original title: New drug for Parkinson's disease (PD)! Ipsen and IRLAB signed an exclusive license agreement: to obtain a new dopamine D3 receptor antagonist mesdopetam!